{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:55:15Z","timestamp":1790009715163,"version":"4.0.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Takayasu arteritis (TAK) is an idiopathic systemic disease characterized by granulomatous inflammation of the aorta and its branches. TAK can cause multiple vascular injuries throughout the body, mainly arterial stenosis and aneurysms. In severe cases, it can even lead to fatal hemorrhage, infarction and other serious complications, posing a serious threat to the patient\u2019s life and health. Few studies have shown that drug treatment can improve or reverse its vascular stenosis. This study describes a 19-year-old woman diagnosed with TAK who had multiple vascular stenosis at the time of the disease. In an early and timely manner as well as up to seven years after a full course of tolizumab, her vascular wall thickening improved and previously stenotic vessels were recanalized. We believe that early use of tocilizumab in patients with TAK can improve vascular lesions. To our knowledge, this study is the first case to find complete recanalization of stenotic vessels after the use of tocilizumab, and the pre- and post-test and examination data are complete. In addition, we summarized the cases of improvement of vascular lesions after tocilizumab treatment of TAK, and preliminarily compared the efficacy and safety of tocilizumab and TNFi in TAK. We speculate that early and adequate use of tocilizumab could reverse early inflammatory vessel wall thickening and stenosis, and we found, through further literature review, that its efficacy was comparable to that of TNF inhibitors<\/jats:p>","DOI":"10.3389\/fimmu.2025.1593770","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:29:13Z","timestamp":1750915753000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis?"],"prefix":"10.3389","volume":"16","author":[{"given":"Congqi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223482","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41774","article-title":"2021 American college of rheumatology\/Vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-060622-100940","article-title":"New therapeutic approaches to large-vessel vasculitis","volume":"75","author":"Kaymakci","year":"2024","journal-title":"Annu Rev Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330811","article-title":"The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.23373","article-title":"Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody","volume":"58","author":"Nishimoto","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12872-019-1066-7","article-title":"Regressed coronary ostial stenosis in a young female with Takayasu arteritis: a case report","volume":"19","author":"Yokokawa","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-1384","article-title":"Successful tocilizumab treatment in a child with refractory Takayasu arteritis","volume":"130","author":"Bravo Manche\u00f1o","year":"2012","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.11.026","article-title":"Tocilizumab and refractory Takayasu disease: four case reports and systematic review","volume":"17","author":"Decker","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e004819","DOI":"10.1161\/CIRCIMAGING.116.004819","article-title":"Dramatic response to tocilizumab before emergency surgery in severe active Takayasu disease","volume":"9","author":"Risse","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.09.051","article-title":"Takayasu arteritis: JACC focus seminar 3\/4","author":"Joseph","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225630","article-title":"Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu\u2019s arteritis","volume":"83","author":"Fang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.027","article-title":"Pleiotropy and specificity: insights from the interleukin 6 family of cytokines","volume":"50","author":"Murakami","year":"2019","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.2741\/4054","article-title":"IL-6, IL-17 and STAT3: a holy trinity in auto-immunity","volume":"17","author":"Camporeale","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.39037","article-title":"Th1 and Th17 cytokines drive inflammation in Takayasu arteritis","volume":"67","author":"Saadoun","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaut.2019.01.010","article-title":"Autophagy promotes aortic adventitial fibrosis via the IL-6\/Jak1 signaling pathway in Takayasu\u2019s arteritis","volume":"99","author":"Chen","year":"2019","journal-title":"J Autoimmun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e20190347","DOI":"10.1084\/jem.20190347","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejim.2024.04.004","article-title":"Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis","volume":"126","author":"Sun","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key040","article-title":"Takayasu arteritis: advanced understanding is leading to new horizons","volume":"58","author":"Tombetti","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab684","article-title":"Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial","volume":"61","author":"Nakaoka","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2018.04.002","article-title":"Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients","volume":"91","author":"Mekinian","year":"2018","journal-title":"J Autoimmun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1084558","article-title":"Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis","volume":"14","author":"Kang","year":"2023","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.07.012","article-title":"Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature","volume":"46","author":"Batu","year":"2017","journal-title":"Semin Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead387","article-title":"Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study","volume":"63","author":"Wang","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103275","DOI":"10.1016\/j.autrev.2023.103275","article-title":"The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis","volume":"22","author":"Misra","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab635","article-title":"Efficacy and safety of TNF-\u03b1 antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients","volume":"61","author":"Mekinian","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.09.010","article-title":"Biologic treatments in Takayasu\u2019s Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab","volume":"51","author":"Alibaz-Oner","year":"2021","journal-title":"Semin Arthritis Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014321","article-title":"Efficacy of biological-targeted treatments in takayasu arteritis: multicenter, retrospective study of 49 patients","volume":"132","author":"Mekinian","year":"2015","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1136\/annrheumdis-2018-214642","article-title":"Disease progression of Takayasu arteritis in two patients treated with tocilizumab","volume":"79","author":"Sanchez-Alvarez","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1593770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:29:14Z","timestamp":1750915754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1593770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2025.1593770"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1593770","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"article-number":"1593770"}}